Expression profile analysis of circular RNA in multiple myeloma versus iron-deficiency anemia
Ontology highlight
ABSTRACT:
ORGANISM(S): Homo sapiens
PROVIDER: GSE208782 | GEO | 2022/07/22
REPOSITORIES: GEO
Similar Datasets
Project description:Expression profile analysis of circular RNA in multiple myeloma versus iron-deficiency anemia
| PRJNA860994 | ENA
Project description:Immunomodulatory drugs (IMiDs), such as lenalidomide and pomalidomide, may induce significant remissions in multiple myeloma (MM) patients, but relapses are frequently observed and the underlying molecular mechanisms for this are not completely understood. Circular RNAs (circRNAs) constitute an emerging class of non-coding RNAs with important roles in cancer. Here, we profiled genome-wide expression patterns of circRNAs in IMiD sensitive MM cells and their resistant counterparts as well as in IMiD resistant cells treated with specific epigenetic drugs alone or in combination. We found that genome-wide circRNA expression patterns reflect IMiD-sensitivity and ciRS-7 (also known as CDR1as) was the most downregulated circRNA upon acquired resistance. The depletion of ciRS-7 correlated with increased methylation levels of the promoter CpG island of its host gene, LINC00632. Expression of LINC00632 and ciRS-7 was partly restored by treatment with a combination of an EZH2 inhibitor (EPZ-6438) and a DNA methyl transferase inhibitor (5-azacytidine), which also restores the IMiD sensitivity of the cells. However, knockdown of ciRS-7 did not affect IMiD sensitivity and we found that ciRS-7 also becomes epigenetically silenced after prolonged cell culture without drug-exposure. In conclusion, we found that genome-wide circRNA expression patterns reflect IMiD sensitivity in an in vitro model of acquired resistance.
2021-02-19 | GSE161960 | GEO
Project description:Multiple Myeloma cell line MM.1S performed ChIP-seq analysis using anti-c-Fos antibody.
2022-01-30 | GSE194381 | GEO
Project description:Despite the development of novel therapeutic agents, multiple myeloma (MM) remains incurable, owing mainly to inevitable relapse in almost all patients. Some relapses occur as extramedullary disease (EMD), which is rare but is the most aggressive event in MM patients. Extramedullary myeloma (EMM) has extraordinary heterogeneous biological and clinical features. Previous studies have shown that expression levels of LncRNAs and mRNAs in different stages of MM are different. This study analyzes the expression levels of LncRNAs and mRNAs in primary plasma cells (PCs) from MM and EMM patients.
2023-03-01 | GSE147841 | GEO
Project description:Multiple myeloma is a relatively common B-cell malignancy that is currently incurable. Certain recurrent genetic abnormalities characteristics of different genetic subtypes have been described. Hyperdiploid myeloma characterized by recurrent trisomies is the most common genetic subtypes. However little is know about it's biology. Another common genetic abnormality is chromosome 13 deletion which is also associated with inferior prognosis. This abnormality is already present at the pre-malignant MGUS stage and is clonally selected with disease progression. Although it is biologically and clinically important the molecular consequence of chromosome 13 deletion is unknown. Experiment Overall Design: Hyperdiploid myeloma was identified using FISH. The gene expression profile of hyperdiploid MM is compared to that of non-hyperdiploid myeloma to identify differentially expressed genes. Molecular heterogeneity within H-MM is analyzed using unsupervised techniques. The distinctive subgroups identified are also tested in MGUS/SMM and NH-MM. The clinical relevance of these subtypes of hyperdiploid myeloma is then analyzed by correlating with relevant clinical information. Chromosome 13 deleted and undeleted MM are identified by FISH and their gene expression profile compared to identify molecular signature.
2008-06-15 | E-GEOD-6477 | biostudies-arrayexpress
Project description:To investigate the role of iron(FeAc) on bortezomib-induced drug resistance of multiple myeloma cells, we administrated MM.1S with iron and bortezomib
2022-10-07 | GSE214766 | GEO
Project description:Purpose:It has been shown that circular RNA (circRNA) is a key regulatory factor in development and progression of human tumors. However, the working mechanism and clinical significance of most circRNAs remain unknown in human cancer, including multiple myeloma (MM), a hematologic malignancy. Patients and methods:In the present study, high-throughput circRNA microarray was combined with bioinformatics to identify differentially expressed circRNAs in MM. The hsa_circ_0007841 expressions were shown in MM tissues of 86 patients and drug-resistant cell lines and pathological features were detected. Further, the relationship between hsa_circ_0007841 expressions in the MM tissues and pathological features of MM patients were discussed. The role of hsa_circ_0007841 as a potential biomarker and therapeutic target was analyzed. Results:Our results indicated that in MM tissues collected from patients, MM cell lines and drug-resistant cell lines, the hsa_circ_0007841 expression was significantly upregulated. A close connection with prognosis was observed. That is, hsa_circ_0007841 upregulation was correlated with chromosomal aberrations, such as gain 1q21, t(4:14) and mutations in ATR and IRF4 genes. This finding was further verified in large samples. Finally, bioinformatics analysis indicated interaction that 8 differentially expressed miRNAs and 10 candidate mRNAs interacted with hsa_circ_0007841. These results sheds new light on the basic functional research in the future. Conclusion:It was reported for the first time that hsa_circ_0007841 was significantly upregulated in MM. Our study indicated that hsa_circ_0007841 may be a novel biomarker for MM and involved in the progression of MM.
2020-04-10 | GSE133058 | GEO
Project description:The objective of this study is to identify genes involved in the pathogenesis of multiple myeloma (MM). In this study, we performed gene expression profiling of a total of 29 samples consisting of 19 clinical specimens, 7 myeloma cell lines and 3 normal samples. The microarray data were analysed by GeneSpring Software v14.9. A total of 5124 DEGs were identified in MM group vs control group (fold change≥2.0; P<0.05). Out of 5124 DEGs, 2696 and 2428 genes were up-regulated and down-regulated, respectively in MM group compared to the normal control group.
2022-07-20 | GSE72213 | GEO
Project description:In multiple myeloma (MM), endothelial progenitor cells (EPCs) regulate tumor angiogenesis and disease progression. They share a common bone marrow microenvironment with myeloma tumor cells. CD138+ tumor plasma cells from 12 newly diagnosed patients with advanced MM were examined for genomic instability by RNA microarrays to assess changes in gene expression.
2011-04-02 | GSE28327 | GEO
Project description:<p>The Multiple Myeloma Research Foundation (MMRF) CoMMpass (Relating <u>C</u>linical <u>O</u>utcomes in <u>MM</u> to <u>P</u>ersonal <u>Ass</u>essment of Genetic Profile) trial (NCT01454297) is a longitudinal observation study of 1000 newly diagnosed myeloma patients receiving various standard approved treatments that aim at collecting tissue samples, genetic information, Quality of Life (QoL) and various disease and clinical outcomes over 10 years.</p>
| phs000748 | dbGaP